Material no.: unknown batch no.: unknown.It was reported that the patient experienced skin irritation from chloraprep dressing kits.Per medwatch: this [pt info omitted] patient began therapy with remodulin (treprostinil sodium, concentration 2.5 mg/ml) on (b)(6) 2020 for primary pulmonary arterial hypertension.The current dose was reported as 0.046 ug/kg, continuous via intravenous route.On an un reported date in 2020, the patient experienced the event of skin irritation from chloraprep dressing kits (dermatitis contact).Action taken with iv remodulin and chloraprep was not reported for the event of dermatitis contact.At the time of reporting, the outcome of dermatitis contact was unknown.The reporter did not provide causality for the event of dermatitis contact.Diagnosis for use (continued): primary pulmonary arterial hypertension (pulmonary arterial hypertension), drug use for unknown indication (product used for unknown indication).Concomitant medical products (continued): esbriet (pirfenidone).
|
No additional information was provided by united therapeutics.Propharma did reach out to obtain with no success.Should additional information be available in the future, the complaint will be re-opened and investigated.All complaints are reviewed during monthly quality/safety meetings.In addition, complaints are trended at monthly quality data analyst meetings and quarterly plant management review meetings.
|